Zynerba Pharmaceuticals Inc on Wednesday delayed the timeline for reporting key data from a trial of its cannabis-based drug to treat a rare genetic disorder, citing difficulties in enrolling patients amid a rise in respiratory illnesses.
The company's experimental drug is currently undergoing a late-stage study in patients between 3 and 17 years of age suffering from Fragile X syndrome, which is one of the most common causes of inherited intellectual disability that impact about 1 in 7,000 males and 1 in 11,000 females, according to the U.S. Centers for Disease Control and Prevention (CDC).
https://finance.yahoo.com/news/1-zynerba-delays-genetic-disorder-122924326.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.